Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00950911 · OUTCOME

Number of Participants Survived

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only · Source last updated 2014-02-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

Analysis population: Full Analysis Set

Groups in this outcome

Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W

This cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.

Denosumab 120 mg Q4W / Denosumab 120 mg Q4W

This cohort received Denosumab 120 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W17
Denosumab 120 mg Q4W / Denosumab 120 mg Q4W18

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W13Not reportedNot reportedNot reportedNot reported
Denosumab 120 mg Q4W / Denosumab 120 mg Q4W12Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        12
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    2. group Id
      OG001
      value
      18
    units
    Participants
groups
  1. description
    This cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.
    id
    OG000
    title
    Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W
  2. description
    This cohort received Denosumab 120 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.
    id
    OG001
    title
    Denosumab 120 mg Q4W / Denosumab 120 mg Q4W
param Type
NUMBER
population Description
Full Analysis Set
reporting Status
POSTED
time Frame
2 years
title
Number of Participants Survived
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice